Research Paper Volume 14, Issue 18 pp 7568—7586
Novel TRKB agonists activate TRKB and downstream ERK and AKT signaling to protect Aβ-GFP SH-SY5Y cells against Aβ toxicity
Figure 1. LM-031 and analogous compounds. (A) Structure and formula of LM-031 and analogs LMDS-1 to -4 and coumarin backbone. (B) Molecular weight (MW), hydrogen bond donor (HBD), hydrogen bond acceptor (HBA), calculated octanol-water partition coefficient (cLogP), polar surface area (PSA), and predicted blood-brain barrier (BBB) score of these compounds. (C) Aβ aggregation inhibition of curcumin (as a positive control), coumarin, LM-031 and analogs (5–20 μM) by the thioflavin T assay (n = 3). To normalize, the relative thioflavin T fluorescence of Aβ42 without compound treatment was set at 100%. Shown below are the EC50 values. (D) Radical scavenging activity of kaempferol (as a positive control), coumarin, LM-031 and analogs (10–160 μM) on DPPH (n = 3). Shown below are the EC50 values.